Open AccessAntiaging Therapies, Cognitive Impairment, and Dementia
Author(s) -
Devin Wahl,
Rozalyn M. Anderson,
David G. Le Couteur
Publication year - 2019
Publication title -
the journals of gerontology. series a, biological sciences and medical sciences
Language(s) - English
Resource type - Journals
eISSN - 1758-535X
pISSN - 1079-5006
DOI - 10.1093/gerona/glz135
Subject(s) - dementia , disease , brain aging , cognitive aging , life span , cognitive impairment , neuroscience , healthy aging , cognitive decline , medicine , cognition , alzheimer's disease , psychology , gerontology
Aging is a powerful risk factor for the development of many chronic diseases including dementia. Research based on disease models of dementia have yet to yield effective treatments, therefore it is opportune to consider whether the aging process itself might be a potential therapeutic target for the treatment and prevention of dementia. Numerous cellular and molecular pathways have been implicated in the aging process and compounds that target these processes are being developed to slow aging and delay the onset of age-associated conditions. A few particularly promising therapeutic agents have been shown to influence many of the main hallmarks of aging and increase life span in rodents. Here we discuss the evidence that some of these antiaging compounds may beneficially affect brain aging and thereby lower the risk for dementia.